Search Results

There are 27649 results for: content related to: Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan

  1. An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia

    Asia-Pacific Journal of Clinical Oncology

    Volume 7, Issue s2, June 2011, Pages: 13–21, John Wen-Cheng CHANG, Sumitra THONGPRASERT, Elaine WRIGHT, Kenneth TSANG, Heung Tae KIM, Myung-Ju AHN, Joo-Hang KIM, Jin Hyoung KANG, Sang-We KIM and Stefan WALZER

    Version of Record online : 18 MAY 2011, DOI: 10.1111/j.1743-7563.2011.01398.x

  2. You have full text access to this Open Access content
    Tumor response and clinical toxicity associated with second-line chemotherapy regimens for advanced non-squamous non-small cell lung cancer: A retrospective cohort study

    Thoracic Cancer

    Volume 5, Issue 5, September 2014, Pages: 365–376, Chengping Hu, Yan Wang, Jianhua Chen, Shengqi Wu, Xiaoling Li, Yuqin Wang, Yicheng Yang, Narayan Rajan, Manny Papadimitropoulos, Qiong Xiao, Huan Zhan and Wendong Chen

    Version of Record online : 25 AUG 2014, DOI: 10.1111/1759-7714.12102

  3. Pemetrexed induces both intrinsic and extrinsic apoptosis through ataxia telangiectasia mutated/p53-dependent and -independent signaling pathways

    Molecular Carcinogenesis

    Volume 52, Issue 3, March 2013, Pages: 183–194, Tsung-Ying Yang, Gee-Chen Chang, Kun-Chieh Chen, Hsiao-Wen Hung, Kuo-Hsuan Hsu, Chi-Hao Wu, Gwo-Tarng Sheu and Shih-Lan Hsu

    Version of Record online : 15 NOV 2011, DOI: 10.1002/mc.21842

  4. Pemetrexed, a Novel Antifolate Therapeutic Alternative for Cancer Chemotherapy

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 26, Issue 5, May 2006, Pages: 641–654, Leticia R. Villela, Brad L. Stanford and Dr. Sachin R. Shah

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.26.5.641

  5. You have free access to this content
    Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01)

    Cancer

    Volume 118, Issue 24, 15 December 2012, Pages: 6234–6242, Jong-Mu Sun, Ki Hyeong Lee, Sang-we Kim, Dae Ho Lee, Young Joo Min, Hwan Jung Yun, Hoon Kyo Kim, Hong Suk Song, Yeul Hong Kim, Bong-Seog Kim, In Gyu Hwang, Keehyun Lee, Sook Jung Jo, Jae Won Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn and for the Korean Cancer Study Group (KCSG)

    Version of Record online : 6 JUN 2012, DOI: 10.1002/cncr.27630

  6. Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective

    Asia-Pacific Journal of Clinical Oncology

    Volume 8, Issue 1, March 2012, Pages: 53–61, Sumitra THONGPRASERT, Sirana TINMANEE and Unchalee PERMSUWAN

    Version of Record online : 28 FEB 2012, DOI: 10.1111/j.1743-7563.2012.01528.x

  7. You have full text access to this Open Access content
    Prospective phase II study of cisplatin plus pemetrexed with maintenance of pemetrexed for advanced non-squamous cell non-small cell lung cancer in Japan

    Thoracic Cancer

    Volume 5, Issue 4, July 2014, Pages: 289–296, Kazuhiro Asami, Masaaki Kawahara, Tomonori Hirashima, Hidekazu Suzuki, Kyoichi Okishio, Naoki Omachi, Motohiro Tamiya, Akihiro Tamiya, Aya Hirooka, Keiko Nakao, Taisuke Tsuji and Shinji Atagi

    Version of Record online : 3 JUL 2014, DOI: 10.1111/1759-7714.12091

  8. You have free access to this content
    Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non–small cell lung cancer

    Cancer

    Volume 121, Issue 6, March 15, 2015, Pages: 883–892, Robert C. Doebele, David Spigel, Mustapha Tehfe, Sachdev Thomas, Martin Reck, Sunil Verma, Janice Eakle, Frederique Bustin, Jerome Goldschmidt Jr, Dachuang Cao, Ekaterine Alexandris, Sergey Yurasov, D. Ross Camidge and Philip Bonomi

    Version of Record online : 6 NOV 2014, DOI: 10.1002/cncr.29132

  9. You have free access to this content
    Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer

    Cancer

    Volume 118, Issue 19, 1 October 2012, Pages: 4694–4705, Susan Urba, Carla M. L. van Herpen, Tarini Prasad Sahoo, Dong M. Shin, Lisa Licitra, Klara Mezei, Christoph Reuter, Ricardo Hitt, Francesca Russo, Shao-Chun Chang, Anwar M. Hossain, Bente Frimodt-Moller, Andrew Koustenis and Ruey-Long Hong

    Version of Record online : 20 MAR 2012, DOI: 10.1002/cncr.27449

  10. You have free access to this content
    Pemetrexed versus erlotinib in pretreated patients with advanced non–small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study

    Cancer

    Volume 119, Issue 15, 1 August 2013, Pages: 2754–2764, Athanasios Karampeazis, Alexandra Voutsina, John Souglakos, Nikos Kentepozidis, Stelios Giassas, Charalambos Christofillakis, Athanasios Kotsakis, Pavlos Papakotoulas, Ageliki Rapti, Maria Agelidou, Sofia Agelaki, Lambros Vamvakas, George Samonis, Dimitris Mavroudis and Vassilis Georgoulias

    Version of Record online : 9 MAY 2013, DOI: 10.1002/cncr.28132

  11. You have full text access to this Open Access content
    Significance of thymidylate synthase for resistance to pemetrexed in lung cancer

    Cancer Science

    Volume 101, Issue 1, January 2010, Pages: 161–166, Hiroaki Ozasa, Tetsuya Oguri, Takehiro Uemura, Mikinori Miyazaki, Ken Maeno, Shigeki Sato and Ryuzo Ueda

    Version of Record online : 10 SEP 2009, DOI: 10.1111/j.1349-7006.2009.01358.x

  12. You have full text access to this OnlineOpen article
    Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3

    Cancer Science

    Volume 106, Issue 9, September 2015, Pages: 1202–1211, Terufumi Kato, Hiroshige Yoshioka, Isamu Okamoto, Akira Yokoyama, Toyoaki Hida, Takashi Seto, Katsuyuki Kiura, Dan Massey, Yoko Seki and Nobuyuki Yamamoto

    Version of Record online : 25 JUL 2015, DOI: 10.1111/cas.12723

  13. You have full text access to this Open Access content
    Cytotoxic effects of pemetrexed in gastric cancer cells

    Cancer Science

    Volume 96, Issue 6, June 2005, Pages: 365–371, Jee Hyun Kim, Keun-Wook Lee, Yeonjoo Jung, Tai Young Kim, Hye Seon Ham, Hyun-Soon Jong, Kyung Hae Jung, Seock-Ah Im, Tae-You Kim, Noe Kyeong Kim and Yung-Jue Bang

    Version of Record online : 15 JUN 2005, DOI: 10.1111/j.1349-7006.2005.00058.x

  14. You have full text access to this OnlineOpen article
    Clinical effect of pemetrexed as the first-line treatment in Chinese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer

    Thoracic Cancer

    Volume 7, Issue 4, July 2016, Pages: 452–458, Di Ma, Xuezhi Hao, Yan Wang, Puyuan Xing and Junling Li

    Version of Record online : 11 MAY 2016, DOI: 10.1111/1759-7714.12353

  15. You have free access to this content
    SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma

    International Journal of Cancer

    Volume 132, Issue 2, 15 January 2013, Pages: 459–471, Kota Iwahori, Satoshi Serada, Minoru Fujimoto, Barry Ripley, Shintaro Nomura, Hiroyuki Mizuguchi, Kazuki Shimada, Tsuyoshi Takahashi, Ichiro Kawase, Tadamitsu Kishimoto and Tetsuji Naka

    Version of Record online : 17 MAY 2012, DOI: 10.1002/ijc.27611

  16. Audit of patients with mesothelioma treated with pemetrexed in a single institution in Western Australia

    Asia-Pacific Journal of Clinical Oncology

    Volume 6, Issue 4, December 2010, Pages: 350–356, Arman HASANI, Kynan FEENEY, Anna NOWAK and Michael MILLWARD

    Version of Record online : 27 JUL 2010, DOI: 10.1111/j.1743-7563.2010.01316.x

  17. Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma

    Intervention Review

    The Cochrane Library

    John A Green, Yenal Dundar, Susanna R Dodd, Rumona C Dickson and Tom Walley

    Published Online : 24 JAN 2007, DOI: 10.1002/14651858.CD005574.pub2

  18. You have free access to this content
    Review of a promising new agent—pemetrexed disodium

    Cancer

    Volume 97, Issue S8, 15 April 2003, Pages: 2056–2063, Luis Paz-Ares, Susana Bezares, José M. Tabernero, Daniel Castellanos and Hernán Cortes-Funes

    Version of Record online : 1 APR 2003, DOI: 10.1002/cncr.11279

  19. You have free access to this content
    Cost-Effectiveness of Pemetrexed Plus Cisplatin: Malignant Pleural Mesothelioma Treatment in UK Clinical Practice

    Value in Health

    Volume 11, Issue 1, January/February 2008, Pages: 4–12, Anna Cordony, Corinne Le Reun, Antje Smala, James T. Symanowski and Jessamy Watkins

    Version of Record online : 25 JUN 2007, DOI: 10.1111/j.1524-4733.2007.00209.x

  20. You have full text access to this OnlineOpen article
    Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy

    Cancer Medicine

    Volume 5, Issue 10, October 2016, Pages: 2688–2693, Zhengbo Song, Haiyan Su and Yiping Zhang

    Version of Record online : 20 AUG 2016, DOI: 10.1002/cam4.809